Aura: Pioneering Vision Health at MIDO 2025 in Milan

Aura, a trailblazer in the vision health industry, make a remarkable debut at MIDO 2025, one of the most prestigious eyewear exhibitions in Europe. 

Aura’s series of myopia management lenses have already gained significant acclaim. These lenses have successfully obtained the EU CE MDR medical device certification, a testament to their outstanding quality, safety, and effectiveness. Meeting the stringent requirements of European optometrists, Aura has not only published one-year clinical data in SCI-indexed journals but also presented pre-myopia management clinical data, introducing the concept of “prevention and control integration” in myopia management across the entire life cycle.

Last year, Aura initiated a new round of clinical trials at Moorfields Eye Hospital. The half-year clinical data, which was presented at the hospital’s academic conference, was cross-validated with its domestic data, demonstrating the consistent and excellent myopia management effects across different ethnic groups. Additionally, Aura has collaborated with renowned institutions such as the School of Optometry at the University of Montreal in Canada and the Optometry Research Center at Minho University in Portugal. Their joint research on Aura’s myopia management lenses, covering aspects like choroidal volume changes and retinal electrophysiological changes compared with leading international products, has been presented at international optometry conferences, further supporting Aura’s market expansion in Europe.

At MIDO 2025, Aura will showcase not only its popular myopia management lenses like Aura and Aura PRO but also the CureSight vision function training device and EyeSwift PRO vision inspection device. 

Both devices, certified under CE MDR, offer a comprehensive solution for children’s vision health, from myopia prevention and control to vision function inspection and training.